UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000051901
Receipt number R000059225
Scientific Title Safety and Efficacy of Acupuncture in Breast Cancer Survivors with Post-Mastectomy Pain Syndrome.
Date of disclosure of the study information 2023/08/14
Last modified on 2023/08/15 14:00:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety and Efficacy of Acupuncture in Breast Cancer Survivors with Post-Mastectomy Pain Syndrome.

Acronym

ABC-1 study

Scientific Title

Safety and Efficacy of Acupuncture in Breast Cancer Survivors with Post-Mastectomy Pain Syndrome.

Scientific Title:Acronym

ABC-1 study

Region

Japan


Condition

Condition

Post-Mastectomy Pain Syndrome

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the safety and efficacy of acupuncture in breast cancer survivors with post-mastectomy pain syndrome.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in pain intensity (NRS) between baseline and week 16.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Acupuncture and moxibustion

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1) Patients with pathologically diagnosed Stage 1-3 breast cancer after radical surgery
2) Patients undergoing treatment-free follow-up at least 6 months after radical surgery without metastatic recurrence (patients on postoperative endocrine therapy or anti-HER2 therapy are included)
3) Postoperative average pain intensity (NRS) >= 4 over the past 24 hours in the chest, shoulder, or neck on the operated side
4) Age >= 18 years on the date of enrollment
5) ECOG PS 0 or 1 on the date of registration
6) Latest laboratory values within 28 days prior to enrollment (same day of the week 28 days prior to enrollment is acceptable) are
Neutrophils >= 1000/mcL, platelets >= 50,000/mcL
7) No change in pain medication* within 7 days prior to enrollment (same day of the week 7 days prior to enrollment is acceptable)
8) Patients who have given their free and voluntary consent in writing to participate in this study


Key exclusion criteria

1) Preoperative chest, shoulder, or neck pain on the operative side
2) Lymphedema in the upper extremity on the operative side
3) Bilateral chest, shoulder, or neck pain
4) Painful comorbidities such as fibromyalgia, inflammatory joint disease, etc.
5) Undergoing chemotherapy (excluding anti-HER2 therapy) or radiotherapy as of the date of registration
6) Has a psychiatric disorder such as severe depression (as determined by the attending physician)
7) Patients with serious complications (as determined by the attending physician)
8) Pregnant or lactating patients
9) Previous acupuncture treatment for PMPS
10) Patients currently enrolled in a clinical trial or a clinical trial affecting this study
11) Other patients deemed by the attending physician to be unsuitable for enrollment in the relevant clinical trial

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Hiroto
Middle name
Last name Ishiki

Organization

National Cancer Center Hospital

Division name

Department of Palliative Medicine

Zip code

104-0045

Address

5-1-1, Tsukiji, Chuoku, Tokyo, Japan

TEL

0335422511

Email

hishiki@ncc.go.jp


Public contact

Name of contact person

1st name Hiroto
Middle name
Last name Ishiki

Organization

National Cancer Center Hospital

Division name

Department of Palliative Medicine

Zip code

1040045

Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan

TEL

0335422511

Homepage URL


Email

hishiki@ncc.go.jp


Sponsor or person

Institute

National Cancer Center

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Meedical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical review board of the National Cancer Center

Address

5-1-1, Tsukiji, Chuoku, Tokyo, Japan

Tel

0335422511

Email

hishiki@ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 08 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2023 Year 07 Month 30 Day

Date of IRB

2023 Year 08 Month 09 Day

Anticipated trial start date

2023 Year 08 Month 14 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 08 Month 14 Day

Last modified on

2023 Year 08 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059225